PITPNB Antibody

What applications are PITPNB antibodies validated for and what are the optimal dilutions?

PITPNB antibodies have been validated for multiple applications, though optimal dilutions vary by manufacturer and specific clone:

The specific dilution should be experimentally determined for your tissue/cell type, as reactivity can vary significantly across samples . For example, PTG Lab's PITPNB antibody (13110-1-AP) requires 1:1000-1:4000 dilution for WB and 1:50-1:500 for IHC applications .

What species reactivity do commercial PITPNB antibodies typically demonstrate?

Most commercially available PITPNB antibodies show reactivity to:

Many antibodies, like Sigma-Aldrich's HPA000528 and Proteintech's 13110-1-AP, have been validated against human, mouse, and rat samples . When selecting an antibody for non-standard models, additional validation is strongly recommended.

How should PITPNB antibodies be stored to maintain optimal activity?

Storage conditions are critical for maintaining antibody efficacy:

• Most PITPNB antibodies should be stored at -20°C for long-term preservation

• For frequent use, short-term storage at 4°C (up to one month) is acceptable

• Avoid repeated freeze-thaw cycles as they can compromise antibody activity

• Many preparations contain glycerol (typically 50%) as a cryoprotectant

• Buffer systems commonly include PBS with 0.02-0.1% sodium azide to prevent microbial growth

For example, the Elabscience PITPNB Polyclonal Antibody is stored in "Phosphate buffered solution, pH 7.4, containing 0.05% stabilizer and 50% glycerol" . Always consult the manufacturer's specific storage recommendations as formulations may vary.

How can I validate the specificity of a PITPNB antibody for my research?

Rigorous validation is essential, particularly for studies where specificity is critical:

• Western blot validation:

  • Use positive control tissues known to express PITPNB (e.g., brain, retina)

  • Verify the observed molecular weight matches the expected ~32 kDa size

  • Include negative controls where PITPNB is absent or knocked down

• Cross-reactivity testing:

  • Test against related proteins (e.g., PITPNA, PITPNG) to confirm specificity

  • In zebrafish studies, antibodies raised against Pitpnbi2 were shown to detect both Pitpnbi1 and Pitpnbi2 but had minimal cross-reactivity with Pitpng and no reactivity with Pitpna

• Knockdown/knockout validation:

  • Perform siRNA knockdown or CRISPR knockout of PITPNB

  • Verify reduced antibody signal in WB or IHC experiments

  • Some publications have used this approach as noted in Proteintech's antibody documentation

• Peptide competition assay:

  • Pre-incubate the antibody with the immunizing peptide

  • Signal should be significantly reduced or eliminated if antibody is specific

For example, in the zebrafish study, affinity-purified anti-Pitpnb serum detected a protein with an apparent molecular mass of approximately 35 kDa in retinal extracts, consistent with the calculated 32 kDa from the primary sequence .

What is known about PITPNB expression patterns in different tissues and how can this guide experimental design?

Understanding expression patterns is crucial for experimental design and interpretation:

• Neural tissues:

  • In zebrafish, Pitpnb is robustly expressed in double cone photoreceptor cells of the retina

  • Expression is particularly strong in the synaptic pedicles of double cone cells

• Cellular localization:

  • PITPNB is primarily cytoplasmic with enrichment at the Golgi apparatus

  • The protein catalyzes phospholipid transfer between membranes

  • Required for COPI complex-mediated retrograde transport from Golgi to ER

• Functional significance:

  • In zebrafish, Pitpnb activity is primarily required for biogenesis/maintenance of double cone photoreceptor cell outer segments

  • Knockdown experiments show morpholino-mediated Pitpnb reduction leads to compromised outer segments

This expression pattern information can guide tissue selection for positive and negative controls, and help interpret staining patterns in experimental samples.

How do I optimize immunostaining protocols for PITPNB detection in retinal tissues?

Based on published methodologies, particularly from zebrafish studies:

• Tissue preparation:

  • For frozen sections: Fix tissues at 25°C for 20 minutes, wash in TBS, post-fix in methanol (5 min, -20°C)

  • For whole-mount preparations: Follow similar fixation but adjust times according to tissue thickness

• Blocking:

  • Use TBS with 5% normal goat serum, 1% DMSO, and 0.1% Triton X-100

  • Block overnight at 4°C for optimal results

• Antibody incubation:

  • Primary antibody: Incubate overnight at 4°C for sections, 48 hours for whole mounts

  • Secondary antibody: Overnight at 4°C after extensive washing in blocking buffer

• Special considerations:

  • For mouse-derived antibodies used on mouse tissues, mouse-on-mouse blocking reagents may be needed to reduce background

  • Antigen retrieval with TE buffer pH 9.0 is recommended for some applications

• Dual labeling experiments:

  • PITPNB antibodies can be effectively combined with other markers

  • In zebrafish retina studies, dual labeling with mAb zpr-1 (which marks double cone cells) showed extensive overlap with Pitpnb in the synaptic pedicles

What controls should be included in experiments using PITPNB antibodies?

Comprehensive controls ensure experimental validity:

• Positive controls:

  • Tissues known to express PITPNB (validated in literature)

  • For WB: K-562 cells, HeLa cells, Raji cells, mouse/rat lung tissue

  • For IHC: Human prostate cancer tissue has been validated

• Negative controls:

  • Primary antibody omission control

  • Isotype control (same species, same immunoglobulin class)

  • Tissues known not to express PITPNB (based on literature)

• Expression knockdown controls:

  • siRNA or morpholino-mediated knockdown samples

  • In zebrafish studies, morpholino-mediated protein knockdown demonstrated specificity

• Peptide competition controls:

  • Pre-absorption of antibody with immunizing peptide should abolish specific signal

  • Some manufacturers like Boster Bio offer blocking peptides that can be purchased for this purpose

What is the relationship between PITPNB and cone photoreceptor cells, and how can this inform research applications?

This represents a specialized research area with significant findings:

• Cell-specific expression:

  • In zebrafish, Pitpnb is primarily expressed in double cone photoreceptor cells

  • Expression is detected throughout the cell but is enriched in synaptic pedicles

  • Double cone cells show a crystalline-like mosaic arrangement in zebrafish retina

• Functional significance:

  • Pitpnb activity is required for biogenesis/maintenance of double cone photoreceptor cell outer segments

  • Morpholino-mediated Pitpnb knockdown leads to compromised outer segments

  • Knockdown also causes loss of immunoreactivity with zpr-1 (Arr3L) antibody, a marker for double cone cells

• Co-localization studies:

  • Dual labeling with mAb zpr-1 showed complete correspondence between zpr-1 and Pitpnb-containing cells

  • This enables identification of double cone cells in complex retinal tissues

• Structural relationships:

  • When viewed at the level of photoreceptor cell synaptic termini, Pitpnb is arranged in repeating rows corresponding to the organization of double cone cells

  • Each labeled pedicle consists of fused pedicles from double cone cell pairs

This specific relationship presents opportunities for using PITPNB antibodies as markers for certain photoreceptor populations in retinal research.

Why might observed molecular weight of PITPNB differ from the calculated weight in Western blot experiments?

Several factors can explain discrepancies between observed and expected molecular weights:

• Post-translational modifications:

  • Phosphorylation, glycosylation, or other modifications can alter migration

  • PITPNB's involvement in phospholipid pathways may subject it to regulatory modifications

• Technical factors:

  • Gel percentage, running conditions, and buffer composition can affect migration

  • Reference marker calibration differences between labs

• Isoform variation:

  • Alternative splicing can result in different protein sizes

  • Human PITPNB has multiple transcript variants

• Sample preparation:

  • Denaturation conditions, reducing agents, and heating times can influence apparent size

  • Protein-lipid interactions may persist under some conditions

As noted by Elabscience, "The actual band is not consistent with the expectation. Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates."

How can I minimize cross-reactivity when using PITPNB antibodies in tissues that express related proteins?

PITPNB belongs to a family of related proteins, requiring specific strategies to minimize cross-reactivity:

• Antibody selection:

  • Choose antibodies raised against unique regions (epitopes) of PITPNB

  • C-terminal targeted antibodies may offer better specificity, as in ABIN656906 which targets amino acids 226-254 from the C-terminal region

• Validation approaches:

  • Test antibodies against recombinant PITPNA, PITPNB, and PITPNG proteins

  • In zebrafish studies, antibodies were tested against yeast lysates expressing different PITP isoforms

• Protocol optimization:

  • Increase blocking time/concentration to reduce non-specific binding

  • Use higher dilutions of primary antibody to enhance specificity

  • Include competitive inhibitors of non-specific binding

• Data analysis:

  • Compare staining patterns with published expression data for PITPNB

  • In dual-labeling experiments, verify co-localization with cell-type specific markers

What are the best approaches for using PITPNB antibodies in co-localization studies?

Co-localization studies require careful planning and execution:

• Antibody compatibility:

  • Ensure primary antibodies are from different host species to avoid cross-reactivity

  • When using mouse-derived PITPNB antibodies on mouse tissues, specialized blocking is required

• Documented successful combinations:

  • PITPNB antibodies pair well with zpr-1 (Arr3L) for double cone cell studies in zebrafish

  • "Dual-labeling of frozen retinal sections with mAb zpr-1 and affinity-purified anti-Pitpnb serum yielded extensively overlapping signals that were most apparent in the region of the synaptic pedicles"

• Imaging considerations:

  • Select fluorophores with minimal spectral overlap

  • For Janelia Fluor 549-conjugated antibodies like NBP2-73421JF549, pair with far-red or blue fluorophores

  • Include single-labeled controls to confirm absence of bleed-through

• Quantitative analysis:

  • Use appropriate co-localization coefficients (Pearson's, Manders', etc.)

  • Establish threshold values based on control samples

How can inconsistent staining results with PITPNB antibodies be addressed?

Variability in staining can arise from multiple sources:

• Fixation sensitivity:

  • Test multiple fixation protocols (PFA, methanol, acetone)

  • Duration of fixation can significantly impact epitope accessibility

  • Zebrafish studies used 20-minute fixation at 25°C followed by methanol post-fixation

• Antigen retrieval optimization:

  • For FFPE sections, test both citrate buffer (pH 6.0) and TE buffer (pH 9.0)

  • Adjust retrieval times and temperatures systematically

• Antibody lot variation:

  • Different lots may have different optimal working dilutions

  • Validate each new lot against previously successful conditions

• Species/tissue differences:

  • Expression levels vary across tissues and developmental stages

  • Some tissues might require permeabilization optimization (e.g., detergent concentration)

• Technical approach:

  • For frozen sections vs. whole-mount preparations, incubation times differ significantly (overnight vs. 48 hours)

  • Signal amplification systems may help with low-expression tissues

How have PITPNB antibodies contributed to understanding phosphoinositide signaling pathways?

PITPNB antibodies have enabled several key discoveries:

• Membrane trafficking insights:

  • PITPNB is required for COPI complex-mediated retrograde transport from Golgi to ER

  • Antibodies have helped define subcellular localization at the Golgi apparatus

• Tissue-specific functions:

  • In zebrafish, PITPNB antibodies revealed essential roles in photoreceptor outer segment integrity

  • "Morpholino-mediated protein knockdown experiments demonstrate Pitpnb activity is primarily required for biogenesis/maintenance of the double cone photoreceptor cell outer segments in the developing retina"

• Protein-protein interactions:

  • Co-immunoprecipitation studies using PITPNB antibodies have identified interaction partners

  • These interactions help place PITPNB within cellular signaling networks

• Developmental biology applications:

  • Contrasting functions of PITPNB vs. PITPNA in zebrafish development

  • "Pitpnb activity is primarily required for biogenesis/maintenance of the double cone photoreceptor cell outer segments in the developing retina. By contrast, Pitpna activity is essential for successful navigation of early developmental programs."

What are the methodological differences between using PITPNB antibodies for studying fixed tissues versus live-cell imaging?

These applications require different antibody properties and methodologies:

• Fixed tissue applications:

  • Conventional IHC/IF applications use permeabilized fixed tissues

  • Both polyclonal and monoclonal antibodies work well in these applications

  • Signal amplification systems can enhance detection sensitivity

• Live-cell limitations:

  • Standard PITPNB antibodies cannot penetrate intact cell membranes

  • For live imaging, alternative approaches are needed:

    • Fluorescently-tagged PITPNB expression constructs

    • Cell-penetrating antibody derivatives (though not widely reported for PITPNB)

    • Labeled binding partners or substrates

• Specialized applications:

  • Pre-conjugated fluorescent antibodies like NBP2-73421JF549 (Janelia Fluor 549-labeled) offer advantages for super-resolution microscopy in fixed tissues

  • For developmental studies in transparent organisms like zebrafish embryos, whole-mount immunostaining protocols with extended incubation times (48 hours) provide better penetration

How can PITPNB antibodies be used to investigate disease mechanisms in retinal disorders?

Based on the established role of PITPNB in photoreceptor cell biology:

• Potential disease applications:

  • Retinal degeneration disorders

  • Cone-rod dystrophies

  • Age-related macular degeneration

• Methodological approaches:

  • Compare PITPNB expression/localization between normal and diseased retinal tissues

  • Use dual labeling with cell death markers to assess correlation with degeneration

  • Monitor PITPNB expression changes during disease progression

• Animal model applications:

  • Use PITPNB antibodies to assess photoreceptor integrity in disease models

  • "Pitpnb morphants exhibit the unanticipated loss of immunoreactivity of double cone cells with the previously uncharacterized zpr-1 antigen – another specific marker for double cone cells"

  • This relationship between Pitpnb and Arr3L (zpr-1) suggests potential mechanistic links to explore in disease states

• Therapeutic monitoring:

  • PITPNB antibodies could potentially assess restoration of normal expression/localization following experimental therapies

  • Changes in PITPNB patterns might serve as biomarkers for treatment response

This specialized application builds on the understanding that "the linkage between Pitpnb dysfunction, defective outer segment morphology in double cone photoreceptor cells, and altered status of a double cone cell-specific arrestin, is a compelling one" .

How do monoclonal and polyclonal PITPNB antibodies compare for different research applications?

Different antibody types offer distinct advantages:

For example, the monoclonal OTI6H10 antibody conjugated to Janelia Fluor 549 is particularly suitable for high-resolution immunofluorescence applications , while polyclonal antibodies like PACO11262 may offer better sensitivity for detecting PITPNB in western blots .

What are the considerations for using PITPNB antibodies across different model organisms?

Cross-species applications require careful validation:

• Epitope conservation:

  • Human PITPNB shows high homology with mouse and rat orthologs

  • Zebrafish studies demonstrated that antibodies raised against Pitpnbi2 detected both Pitpnbi1 and Pitpnbi2 with similar efficiency

  • Sequence alignment between species can predict antibody cross-reactivity

• Validation strategies:

  • Always validate antibodies in each new species with western blots

  • Include positive and negative control tissues

  • Consider using tissues from knockout/knockdown models as specificity controls

• Species-specific considerations:

  • When using mouse-derived antibodies on mouse tissues, use Mouse-On-Mouse blocking reagents to reduce background

  • Tissue preparation protocols may need species-specific optimization

• Reported cross-reactivity:

  • Many commercial antibodies report reactivity across human, mouse, and rat

  • Zebrafish-specific studies provide protocols for this model organism

What critical parameters must be considered when using PITPNB antibodies in quantitative analyses?

Quantitative applications demand rigorous standardization:

• Standard curve generation:

  • Use recombinant PITPNB protein at known concentrations

  • Establish linear detection range for each antibody and application

• Normalization strategies:

  • For western blots, normalize to appropriate housekeeping proteins

  • For IHC/IF, use internal controls within the same tissue section

  • Include calibration standards across different experiments

• Image acquisition parameters:

  • Maintain consistent exposure settings, gain, offset

  • Avoid saturated pixels, which compromise quantitation

  • Collect data within the linear range of the detector

• Procedural standardization:

  • Standardize all protocol steps: fixation time, antibody incubation, development time

  • Process all samples simultaneously when possible

  • Include reference samples across different experimental runs

• Statistical approaches:

  • Account for batch effects in analysis

  • Use appropriate statistical tests based on data distribution

  • Consider power analysis to determine required sample sizes

For example, in zebrafish retina studies, whole-mount preparations were carefully standardized to ensure comparable antibody penetration across samples .

How might PITPNB antibodies contribute to understanding lipid-mediated signaling in neurological disorders?

Given PITPNB's role in phospholipid transport and demonstrated importance in neural tissues:

• Potential research applications:

  • Investigation of PITPNB expression/localization in neurodegenerative disease models

  • Assessment of PITPNB's relationship with lipid metabolism in neural tissues

  • Studies of PITPNB's role in membrane trafficking in neurons

• Methodological approaches:

  • Combine PITPNB immunostaining with lipid probes in neural tissues

  • Use PITPNB antibodies in proximity ligation assays to identify novel interaction partners

  • Employ super-resolution microscopy with fluorescently-labeled PITPNB antibodies to study subcellular localization in neurons

• Translational potential:

  • PITPNB's involvement in photoreceptor maintenance suggests possible roles in other specialized neurons

  • Changes in PITPNB expression or localization might serve as biomarkers for lipid metabolism dysfunction in neural tissues

The established role of PITPNB in "lipid metabolism and intracellular signaling pathways" and its "involvement in lipid transport and lipid-mediated signaling processes" makes it a promising target for studies of neurological disorders with metabolic components .

What recent methodological advances might enhance the utility of PITPNB antibodies in research?

Several technological developments show promise:

• Advanced microscopy applications:

  • Super-resolution microscopy with directly conjugated fluorescent antibodies like NBP2-73421JF549

  • Expansion microscopy to physically enlarge specimens for enhanced resolution

  • Light-sheet microscopy for rapid 3D imaging of intact tissues with PITPNB antibodies

• Multiplexing approaches:

  • Sequential immunostaining with antibody stripping/quenching between rounds

  • Mass cytometry (CyTOF) with metal-conjugated PITPNB antibodies

  • Spectral imaging to separate closely overlapping fluorophores in co-localization studies

• Single-cell applications:

  • Integration with single-cell RNA-seq data to correlate protein expression with transcriptomics

  • Spatial transcriptomics combined with PITPNB immunostaining

• Proximity-based methods:

  • Proximity ligation assays to detect PITPNB interactions with binding partners

  • APEX2 proximity labeling with PITPNB antibodies to identify neighboring proteins

These approaches could significantly expand our understanding of PITPNB's functional interactions in complex cellular contexts.